Page 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON , DC 20549 FORM 20 - F ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 Commission File No .: 001-38370 CollPlant Biotechnologies Ltd. ( Exact name of registrant as specified in its charter ) Translation of registrant's name into English : Not applicable State of Israel ( Jurisdiction of incorporation or organization ) 4 Oppenheimer , Weizmann Science Park Rehovot 7670104 , Israel Tel : +972 73 232 5600 ( Address of principal executive offices ) Yehiel Tal Chief Executive Officer +972 73 232 5600 Yehiel@CollPlant.com 4 Oppenheimer , Weizmann Science Park Rehovot 7670104 , Israel ( Name , Telephone , E - mail and / or Facsimile number and Address of Company Contact Person ) Securities registered or to be registered pursuant to Section 12 ( b ) of the Act : Trading Symbol ( s ) CLGN Name of each exchange on which each class is to be registered The Nasdaq Stock Market LLC Title of each class to be registered American Depositary Shares , each representing one ( 1 ) ordinary share , par value NIS 1.50 per share Ordinary shares , par value NIS 1.50 per share * CLGN * The Nasdaq Stock Market LLC * * Not for trading , but only in connection with the registration of the American Depositary Shares pursuant to requirements of the Securities and Exchange Commission . Securities registered or to be registered pursuant to Section 12 ( g ) of the Act : None Securities for which there is a reporting obligation pursuant to Section 15 ( d ) of the Act : None Number of outstanding shares of each of the issuer's classes of capital or common stock as of December 31 , 2020 : 6,963,838 ordinary shares .